COLL · Collegium Pharmaceutical, Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COLL
this stock
Collegium Pharmaceutical, Inc
|
$718.50M | -50.8% | +23.6% | — | 18.6% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.39B | +21.3% | — | — | 0.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$51.90B | — | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.42B | +24.9% | +4.3% | 63.9 | 3.2% |
|
GALDY
Galderma Group AG/ADR
|
$44.48B | -5.6% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COLL | +0.1% | -17.3% | -29.8% | -7.5% | -50.8% |
| SPY | -0.3% | -0.1% | +20.1% | -0.7% | +11.7% |
| vs SPY | +0.4% | -17.2% | -49.9% | -6.8% | -62.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.